Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer

NCT07226427 is registered in ClinicalTrials.gov with Stemline Therapeutics, Inc. as lead sponsor.

NCT NCT07226427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07226427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer
Lead sponsor
Stemline Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 10, 2026
Completion date
June 2, 2028
Enrollment
100 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant ovarian cancer